Newsroom
July 1, 2021
Dr. Dimpy P. Shah, Population Health Sciences/Mays Cancer Center, was included within a story in Yahoo addressing her research in which 94% of the 131 patients in the study produced antibodies three to four weeks after full vaccination, most of which had solid cancers as opposed to cancers in the blood. Read story
June 17, 2021
Middle-aged people with depressive symptoms who carry a genetic variation called apolipoprotein (APOE) ε4 may be more at risk to develop tau protein accumulations in the brain’s emotion- and memory-controlling regions, a new study by researchers from UT Health San Antonio and collaborating institutions suggests.
June 17, 2021
UT Health San Antonio collaborated with University Health as part of the international COVID-19 Prevention Network and enrolled 176 Novavax clinical trial participants in San Antonio for the Phase 3 study, which is called PREVENT-19.
June 15, 2021
This Texas Public Radio news brief is about the biotechnology company Novavax releasing Phase 3 clinical trial results. UT Health San Antonio collaborated with University Health as part of the international COVID-19 Prevention Network and enrolled 176 Novavax clinical trial participants in San Antonio for the Phase 3 study, which is called PREVENT-19. Read the story.
June 15, 2021
Dr. Barbara Taylor, Infectious Diseases, and the great work of the Novavax research team of UT Health San Antonio and University Health, are featured in the San Antonio Business Journal. The local site of the international clinical trial by the COVID-19 Prevention Network enrolled more than 175 participants. Read the story.
June 15, 2021
Dr. Ruth Berggren, Infectious Diseases, Center for Medical Humanities and Ethics, spoke to KSAT 12 TV audiences on the topic that the COVID-19 vaccine can be taken at the same time as other vaccines, according to the CDC. Watch the story.